Revenio Group Corporation: Correction to the stock exchange release published on February 15, 2016

Revenio Group Corporation, Stock Exchange Release, February 15, 2016, at 10.15

Correction to the stock exchange release published on February 15, 2016 at 9.00

In the Financial statement bulletin 1.1.-31.12.2015 published on February 15, 2016 at 9.00 am
the net sales growth percentage of the Revenio Health Tech business segment was presented incorrectly. The incorrect 26.3 per cent on page 4 was corrected to 10.4 per cent.

The corrected Financial statement bulletin for 2015 is attached to this stock exchange release.

Revenio Group Corporation
Olli-Pekka Salovaara

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2015, the Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.